BeiGene currently trades with a PEG ratio of 3.46, based on Jun 3, 2026 data. Dividing the 775 PE ratio by the 224.1% earnings growth rate produces this figure.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 10.65 | 1,519.05 | 142.6% |
| 2024 | N/A | N/A | 27.7% |
| 2023 | N/A | N/A | 56.4% |
| 2022 | N/A | N/A | -23.1% |
| 2021 | N/A | N/A | 19.3% |
| 2020 | N/A | N/A | -23% |
| 2019 | N/A | N/A | -31.2% |
| 2018 | N/A | N/A | -447.1% |
| 2017 | N/A | N/A | 43.3% |
| 2016 | N/A | N/A | 42.3% |
| 2015 | N/A | N/A | -188.9% |
| 2014 | N/A | N/A | -125% |
| 2013 | N/A | N/A | N/A |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 3.68 | 824.92 | 224.1% |
| Dec 2025 | 10.65 | 1,519.05 | 142.6% |
| Sep 2025 | 63.21 | 6,814 | 107.8% |
| Jun 2025 | N/A | N/A | 66.7% |
| Mar 2025 | N/A | N/A | 50% |
| Dec 2024 | N/A | N/A | 27.7% |
| Sep 2024 | N/A | N/A | 9.9% |
| Jun 2024 | N/A | N/A | 69.5% |
| Mar 2024 | N/A | N/A | 59.2% |
| Dec 2023 | N/A | N/A | 56.4% |
| Sep 2023 | N/A | N/A | 57% |
| Jun 2023 | N/A | N/A | 20% |
| Mar 2023 | N/A | N/A | 10.1% |
| Dec 2022 | N/A | N/A | -23.1% |
| Sep 2022 | N/A | N/A | -46% |
With a PEG of 3.46, ONC ranks higher than the Healthcare sector and the industry average.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| ONC BeiGene Ltd. | 3.47 | $31.13B |
| OPK Opko Health Inc | N/A | $1.1B |
| ORGO Organogenesis Holdings Inc | N/A | $319.11M |
According to Jun 3, 2026 figures, ONC's PEG ratio stands at 3.46.
A 3.46 PEG ratio for ONC suggests the stock trades at a premium relative to its growth trajectory.
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Jun 3, 2026, BeiGene carries a PE ratio of 775. Earnings grew at 224.1% over the TTM period ending Mar 2026. Applying the formula, this yields a PEG ratio of 3.46. PEG RATIO(3.46) = PE RATIO(775) / EPS GROWTH(224.1%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.